PMDA drug package insert
リセドロン酸Na錠75mg「サワイ」
PMDA Prescription drug · 沢井製薬株式会社 · package insert Apr 28, 2026
Key facts
| Brand names | リセドロン酸Na錠75mg「サワイ」 |
|---|---|
| Nonproprietary names | リセドロン酸ナトリウム水和物 |
| Companies | 製造販売元／沢井製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 骨粗鬆症治療剤 |
| Therapeutic category codes | 873999 |
| YJ codes | 3999019F3061 |
| Approval numbers | 30700AMX00008000 |
| Package insert edition | 第2版 |
| Package insert date | Apr 28, 2026 |
| PMDA document key | 300119_3999019F3061_1 |
| PMDA company code | 300119 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: